Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06809114 · ClinicalTrials.gov registry record · Phase 1
FIH Study to Evaluate Safety, Tolerability, PK, PD & Preliminary Efficacy of AT03-65 With Advanced Solid Tumors
A Phase 1 study of Solid Tumor, sponsored by Axcynsis Therapeutics Pte.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 83
- Enrollment target
- 1
- Study location
NCT06809114 is a Phase 1 study of Solid Tumor that is actively recruiting participants, run by Axcynsis Therapeutics Pte. The registered enrollment target is 83 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06809114, a Phase 1 study of Solid Tumor, is actively recruiting participants, sponsored by Axcynsis Therapeutics Pte.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 83 participants
- Enrollment target
- 1
- Study location
Study Summary
A Phase I, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AT03-65 in Adults with Advanced Solid Tumors
Conditions Studied
Interventions
- DRUG AT03-65
Study Locations (1)
Oregon
- Oregon Health & Science University (OHSU) - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2026-01-14 |
| Est. Completion | 2028-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06809114
The ClinicalTrials.gov registry entry for NCT06809114 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (62% lower). The listed sponsor is Axcynsis Therapeutics Pte, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which AT03-65 is the first listed.
NCT06809114 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.
Frequently Asked Questions
What is clinical trial NCT06809114 about?
NCT06809114 is a clinical study titled "FIH Study to Evaluate Safety, Tolerability, PK, PD & Preliminary Efficacy of AT03-65 With Advanced Solid Tumors". A Phase I, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AT03-65 in Adults with Advanced Solid Tumors
What is the current status of trial NCT06809114?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 83 participants. The study started on 2026-01-14. Estimated completion is 2028-08.
What conditions does trial NCT06809114 study?
This clinical trial studies the following conditions: Solid Tumor.
What interventions are being tested in trial NCT06809114?
The interventions under investigation include: AT03-65 (DRUG).
Who is sponsoring clinical trial NCT06809114?
This trial is sponsored by Axcynsis Therapeutics Pte, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06809114 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.